Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921741 | 0.79 | MEN1 (0.47) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL17322734 | 0.78 | KDM4E (0.61) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL162660 | 0.78 | MEN1 (0.56) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL2623 | 0.78 | KDM4E (0.66) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL20110445 | 0.76 | MEN1 (0.45) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL20110437 | 0.76 | MEN1 (0.45) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL4073045 | 0.76 | SRC (0.54) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL11799440 | 0.75 | L3MBTL1 (0.48) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL5594628 | 0.75 | SRC (0.59) | SRCKDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL122230 | 0.75 | SRC (0.58) | SRCKDM4EL3MBTL1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-3150616-B1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | SRC 3447/4885KDM4E 3301/4885L3MBTL1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.